Early and sustained haemodynamic improvement with levosimendan compared to intraaortic balloon counterpulsation (IABP) in cardiogenic shock complicating acute myocardial infarction

References

• Hochman J. S., Boland J., Sleeper L. A., Porway M., Brinker J., Col J., et al. Current spectrum of cardiogenic shock and effect of early revascularization on mortality: results of an international registry. Circulation 1995; 91: 873–81
   PubMedGoogle Scholar
• Hochman J. S., Sleeper L. A., Webb J. G., Sanborn T. A., White H. D., Talley J. D., et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock?. N Engl J Med 1999; 341: 625–34
   PubMed Web of Science ®Google Scholar
• Follath F., Cleland J. G. F., Just H., Papp J. G., Scholz H., Peuhkurinen K., et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low‐output heart failure (the LIDO study): a randomised double‐blind trial. Lancet 2002; 360: 196–202
   PubMed Web of Science ®Google Scholar
• Moiseyev V. S., Poder P., Andrejevs N., Ruda M. Y., Golikov A. P., Lazebnik L. B., et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo‐controlled, double‐blind study (RUSSLAN). Eur Heart J 2002; 23: 1422–32
   PubMed Web of Science ®Google Scholar
• Lehmann A., Lang J., Boldt J., Isgro F., Kiessling A. H. Levosimendan in patients with cardiogenic shock undergoing surgical revascularization: a case series. Med Sci Monit 2004; 10: 89–93
   Google Scholar
• De Luca L., Colucci W., Nieminen M., Massie B. M., Gheorghiade M. Evidence‐based use of levosimendan in different clinical settings. Eur Heart J 2006; 27: 1908–20
   PubMed Web of Science ®Google Scholar
• Nieminen M. S., Böhm M., Cowie M. R., Drexler H., Filippatos G. S., Jondeau G., et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 384–416
   PubMed Web of Science ®Google Scholar
• De Luca L., Proietti P., Celotto A., Bucciarelli‐Ducci C., Benedetti G., Di Roma A., et al. Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction. Am Heart J 2005; 150: 563–8
   PubMed Web of Science ®Google Scholar
• Antman E. M., Anbe D. T., Armstrong P. W., Bates E. R., Green L. A., Hand M., et al. ACC/AHA guidelines for the management of patients with ST‐elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2004; 44: E1–E211
   PubMedGoogle Scholar
• Moulopoulos S., Stamatelopoulos S., Petrou P. Intraaortic balloon assistance in intractable cardiogenic shock. Eur Heart J 1986; 7: 396–403
   PubMedGoogle Scholar
• Sanborn T. A., Sleeper L. A., Bates E. R., Jacobs A. K., Boland J., French J. K., et al. Impact of thrombolysis, intra‐aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK?. J Am Coll Cardiol 2000; 36: 1123–9
   PubMed Web of Science ®Google Scholar
• Barron H. V., Every N. R., Parsons L. S., Angeja B., Goldberg R. J., Gore J. M., et al. Investigators in the National Registry of Myocardial Infarction 2. The use of intra‐aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: data from the National Registry of Myocardial Infarction 2. Am Heart J 2001; 141: 933–9
   PubMed Web of Science ®Google Scholar
• Stone G. W., Ohman E. M., Miller M. F., Joseph D. L., Christenson J. T., Cohen M., et al. Contemporary utilization and outcomes of intra‐aortic balloon counterpulsation in acute myocardial infarction: the benchmark registry. J Am Coll Cardiol 2003; 41: 1940–5
   PubMed Web of Science ®Google Scholar
• Van de Werff F., Ardissino D., Betriu A., Cokkinos D. V., Falk E., Fox K. A., et al. Management of acute myocardial infarction in patients presenting with ST‐segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003; 24: 28–66
   Google Scholar
• Fincke R., Hochman J. S., Lowe A. M., Menon V., Slater J. N., Webb J. G., et al. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: A report from the SHOCK trial registry. J Am Coll Cardiol 2004; 44: 340–8
   PubMed Web of Science ®Google Scholar
• Hollenberg S. M., Kavinsky C. J., Parrillo J. E. Cardiogenic shock. Ann Intern Med 1999; 131: 47–59
   PubMed Web of Science ®Google Scholar
• Hochman J. S. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 2003; 107: 2998–3002
   PubMed Web of Science ®Google Scholar
• Sleeper L. A., Ramanathan K., Picard M. H., Lejemtel T. H., White H. D., Dzarvik V., et al. Functional status and quality of life after emergency revascularization for cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol 2005; 46: 266
   PubMed Web of Science ®Google Scholar
• Ohman E. M., Hochman J. S. Aortic counterpulsation in acute myocardial infarction: physiologically important but does the patient benefit?. Am Heart J 2001; 141: 889–92
   Google Scholar
• Ohman E. M., Nanas J., Stomel R. J., Leesar R. J., Nielsen D. W., O'Dea D., et al. Thrombolysis and counterpulsation to improve survival in myocardial infarction complicated by hypotension and suspected cardiogenic shock or heart failure: results of the TACTICS Trial. J Thromb Thrombolysis 2005; 19: 33–9
   PubMed Web of Science ®Google Scholar
• Stone G. W., Marsalese D., Brodie B. R., Griffin J. J., Donohue B., Costantini C., et al. A prospective, randomized evaluation of prophylactic intraaortic balloon counterpulsation in high risk patients with acute myocardial infarction treated with primary angioplasty. Second primary angioplasty in myocardial infarction (PAMI‐II) trial investigators. J Am Coll Cardiol 1997; 29: 1459–67
   PubMedGoogle Scholar
• Berger P. B., Holmes D. R., Jr., Stebbins A. L., Bates E. R., Califf R. M., Topol E. J. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO‐I) trial. An observational study. Circulation 1997; 96: 122–7
   PubMed Web of Science ®Google Scholar
• Santa‐Cruz R. A., Cohen M. G., Ohman E. M. Aortic counterpulsation: a review of the hemodynamic effects and indications for use. Catheter Cardiovasc Interv 2006; 67: 68–77
   PubMed Web of Science ®Google Scholar
• Cotter G., Moshkovitz Y., Kaluski E., Milo O., Nobikov Y., Schneeweiss A., et al. The role of cardiac power and systemic vascular resistance in the pathophysiology and diagnosis of patients with acute congestive heart failure. Eur J Heart Fail 2003; 5: 443–51
   PubMed Web of Science ®Google Scholar
• Morelli A., De Castro S., Teboul J. L., Singer M., Rocco M., Conti G., et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 2005; 31: 638–44
   PubMed Web of Science ®Google Scholar
• Thiele H., Sick P., Boudriot E., Diederich K. W., Hambrecht R., Niebauer J., et al. Randomized comparison of intra‐aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J 2005; 26: 1276–83
   PubMed Web of Science ®Google Scholar
• Jamali I. N., Kersten J. R., Pagel P. S., Hettrick D. A., Warltier D. C. Intracoronary levosimendan enhances contractile function of stunned myocardium. Anesth Analg 1997; 85: 23–9
   PubMed Web of Science ®Google Scholar
• Nijhawan N., Nicolosi A. C., Montgomery M. W., Aggarwal A., Pagel P. S., Warltier D. C. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo‐controlled trial. J Cardiovasc Pharmacol 1999; 34: 219–28
   PubMed Web of Science ®Google Scholar
• Garcia‐González M. J., Domínguez‐Rodríguez A., Ferrer‐Hita J. J., Abreu‐Gonzalez P., Munoz M. B. Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamics. Eur J Heart Fail 2006; 8: 723–8
   PubMed Web of Science ®Google Scholar